Adma Biologics (ADMA) Debt to Equity: 2012-2025
Historic Debt to Equity for Adma Biologics (ADMA) over the last 9 years, with Sep 2025 value amounting to $0.17.
- Adma Biologics' Debt to Equity fell 61.56% to $0.17 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.17, marking a year-over-year decrease of 61.56%. This contributed to the annual value of $0.21 for FY2024, which is 78.54% down from last year.
- Per Adma Biologics' latest filing, its Debt to Equity stood at $0.17 for Q3 2025, which was down 8.84% from $0.18 recorded in Q2 2025.
- Adma Biologics' 5-year Debt to Equity high stood at $1.41 for Q3 2022, and its period low was $0.17 during Q3 2025.
- Over the past 3 years, Adma Biologics' median Debt to Equity value was $0.70 (recorded in 2024), while the average stood at $0.60.
- In the last 5 years, Adma Biologics' Debt to Equity surged by 53.39% in 2022 and then slumped by 78.54% in 2024.
- Adma Biologics' Debt to Equity (Quarterly) stood at $0.67 in 2021, then spiked by 39.86% to $0.94 in 2022, then increased by 2.77% to $0.97 in 2023, then tumbled by 78.54% to $0.21 in 2024, then tumbled by 61.56% to $0.17 in 2025.
- Its Debt to Equity was $0.17 in Q3 2025, compared to $0.18 in Q2 2025 and $0.19 in Q1 2025.